{"id":"https://genegraph.clinicalgenome.org/r/a483977d-70b2-4d89-8bb9-20a540dabb19v3.0","type":"EvidenceStrengthAssertion","dc:description":"The *GAS2L2* gene was first reported in relation to primary ciliary dyskinesia in 2019 (Bustamante-Marin et al., PMID: 30665704). The specific disease entity, primary ciliary dyskinesia 41 (MONDO:0032757, OMIM #618449), is one of at least 45 different primary ciliary dyskinesias distinguished by a single monogenic cause. Affected patients can have childhood onset of symptoms or can be diagnosed as late as in the 6th decade of life (PMID: 36104176, PMID: 30665704). Consistent features among the limited number of well-characterized patients are sinusitis, otitis media, and bronchiectasis. Low nasal nitric oxide levels are observed in some patients, but not others. Adult patients can exhibit infertility. While neonatal respiratory distress and heterotaxy have not been found among the limited number of well-characterized patients, establishing the presence or absence of these symptoms in the patient population will require the emergence and characterization of additional affected individuals (PMID: 30665704). Biopsies of the airway epithelium show cilia with normal axonemal ultrastructure but hyperkinetic beat frequency with a normal waveform. Basal body orientation is disrupted, causing a lack of coordinated directionality of beating among the cilia of each cell. This curation has scored three suspected disease-causing *GAS2L2* variants (two frameshift and one missense), which were reported in two homozygous probands and one compound heterozygous proband in two publications (PMID: 30665704, PMID: 36104176). One of the variants consists of an approximately 4-kilobase deletion affecting not only *GAS2L2* but also a region within the adjacent *RASL10B* locus encoding part of the 3â€™UTR. The molecular mechanism appears to be biallelic loss of function with an autosomal recessive mode of inheritance, characterized in at least some cases by variants predicted to trigger the absence of a gene product. Please note that the limited number of patients and functional assays available has so far precluded a more thorough analysis of molecular mechanism, and an urgent need remains for additional published cases.\n\nThis gene-disease association is also supported by experimental evidence that human and mouse tissues exhibiting the highest levels of *GAS2L2* expression include tissue types relevant to disease and known to have motile cilia, including the fallopian tube, lung, brain, and testis (PMID: 30665704, PMID: 23715323). Within the airway epithelium, the GAS2L2 protein exhibits strong subcellular localization to the base of the cilia and co-localizes with basal body markers (PMID: 30665704). Additional biochemical studies have demonstrated that GAS2L2 interacts through its C-terminal region with microtubule plus ends and with the microtubule plus end-associated protein EB1 (PMID: 24706950, PMID: 22885064, PMID: 12584248). When exogenously expressed, GAS2L2 stabilizes microtubule length (PMID: 24706950) and can promote microtubule bundling (PMID:12584248). The C-terminus of GAS2L2 also interacts with actin microfilaments (PMID: 12584248), including in ciliated cells (PMID: 30665704), consistent with a function in coordinating consistent ciliary basal body orientation relative to the actin cytoskeleton. While GAS2L2 can also interact with the G-protein-coupled A2A adenosine receptor and enhance its adenylate cyclase (cAMP-producing) activity (PMID: 23994616), it is not yet clear whether this function occurs in cell types with motile cilia or to what degree it impacts ciliary beat frequency. Phenotypes of affected human patients are recapitulated by various model organisms with *GAS2L2* loss-of-function, including *Xenopus laevis* embryos and knockout mice. Silencing of two genes orthologous to *GAS2L2* in *Xenopus laevis* embryos recapitulates the human patient phenotype of disoriented ciliary beat directionality and can be rescued by co-injection of human *GAS2L2* mRNA (PMID: 30665704, PMID: 36878953). Respiratory epithelial cells from *Gas2l2* knockout mice recapitulate the human patient features of hyperkinetic ciliary beat frequency, misalignment of basal feet, and disorientation of the ciliary beating pattern in each cell, while exhibiting the additional phenotypes of situs ambiguus and high neonatal mortality (PMID: 30665704). A conditional *Gas2l2* knockout model further shows impaired mucociliary clearance (PMID: 30665704).\n\nIn summary, the evidence linking *GAS2L2* with primary ciliary dyskinesia 41 has reached a score in the moderate range. This association has been repeatedly demonstrated in both research and diagnostic settings, and has been upheld over time without the emergence of contradictory evidence, leading to a Moderate classification. Additional genetic evidence will be required to reach a more definitive gene-disease association. This classification was approved by the ClinGen Motile Ciliopathy GCEP on September 14th, 2023 (SOP Version 9).","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/a483977d-70b2-4d89-8bb9-20a540dabb19","GCISnapshot":"https://genegraph.clinicalgenome.org/r/91afae37-4cfc-4aeb-af0f-26a9596611f3","calculatedEvidenceStrength":"Moderate","changes":[{"id":"cg:classificationChange"},{"id":"cg:newEvidence"},{"id":"cg:sopChange"},{"id":"cg:summaryChange"},{"id":"cg:otherTextChange"}],"contributions":[{"id":"https://genegraph.clinicalgenome.org/r/91afae37-4cfc-4aeb-af0f-26a9596611f3_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10102","date":"2024-01-01T04:14:05.212Z","role":"Publisher"},{"id":"https://genegraph.clinicalgenome.org/r/91afae37-4cfc-4aeb-af0f-26a9596611f3_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10102","date":"2023-09-14T16:00:00.000Z","role":"Approver"}],"curationReasons":["RecurationNewEvidence"],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/91afae37-4cfc-4aeb-af0f-26a9596611f3_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/91afae37-4cfc-4aeb-af0f-26a9596611f3_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a90eed65-5a34-4eea-bac3-f9d5ab0e1991","type":"EvidenceLine","dc:description":"This expression pattern is consistent with patients' lung phenotypes such as sinusitis, bronchiectasis, and otitis media, as well as the fertility issues observed in the single adult patient.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/81799da0-610c-4814-ac85-df016a675707","type":"Finding","dc:description":"GAS2L2 mRNA expression was examined across 9 different human tissues, and primarily detected in those known to contain ciliated cells (brain, lung, testis, and fallopian tube). Among the unciliated tissues, only kidney exhibited high GAS2L2, but not colon, placenta, pancreas, or stomach (Figure 2A). Similar mouse data are shown in Figure S6B. GTEx RNA-seq data (PMID: 23715323) confirm most of these findings by showing that GAS2L2 expression levels are highest in fallopian tube, lung, skeletal muscle, and hypothalamus (brain) tissues.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30665704","rdfs:label":"Human GAS2L2 expression in tissues with motile cilia","demonstrates":{"id":"cg:GeneExpressionA"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/02426fbb-1df5-4c8e-ad69-103093397414","type":"EvidenceLine","dc:description":"This data showing subcellular localization to a key region of the cilia complements the other expression data showing high levels in tissues containing ciliated cells.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4123b615-1799-449c-85c7-995666a4f502","type":"Finding","dc:description":"GAS2L2 was detected by single-cell immunofluorescence and found to localize strongly to the base of the cilia (Figure 2D-1). It also co-localizes with basal body markers such as gamma-tubulin, EB1, centrin-2, and actin (Figure 2F).","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30665704","rdfs:label":"GAS2L2 localization to the base of the cilia","demonstrates":{"id":"cg:GeneExpressionA"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/39aed3d0-a498-4c6a-9488-76d5e20dec55","type":"EvidenceLine","dc:description":"These data convincingly establish GAS2L2 as a cytoskeletal-interacting protein and explain its localization to the basal body where microtubule-containing cilia have an interface with actin microfilaments.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/bbb4c56f-4f9e-4626-9514-e94fab06469d","type":"Finding","dc:description":"The paper contains 6 pieces of evidence that collectively indicate that GAS2L2 (referred to as GAR17) interacts with both microtubules and actin microfilaments (particularly through its C-terminal domain) and promotes microtubule bundling. This evidence is consistent with the phenotype of ciliary dyskinesia and the co-localization of the protein with actin filaments in ciliated cells (PMID: 30665704). Its subcellular localization with basal bodies places it at the interface between the cilia and the actin cytoskeleton. While actin filaments have been linked to ciliary assembly, GAS2L2-deficient cells appear to have hyperkinetic and disoriented movement rather than visible ultrastructural abnormalities.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12584248","rdfs:label":"GAS2L2 interacts with microtubules and microfilaments","demonstrates":{"id":"cg:BiochemicalFunctionB"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/de361588-f61f-4c30-b3ad-12d29e9ce1c2","type":"EvidenceLine","dc:description":"These data further establish the link between GAS2L2 function and regulation of the interactions between microtubules and actin filaments. While other biochemical evidence have been scored as part of this curation, this study adds detail on the interaction with microtubule plus ends specifically, the physical association with EB1, and the ability of exogenous GAS2L2 to exert a stabilizing effect on microtubule dynamics.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b87ac529-4384-40c5-9892-8f4b9d758795","type":"Finding","dc:description":"These biochemical data link GAS2L2 to a function in regulating microtubule stability in coordination with the plus-end-associated EB1 protein and through cross-talk with actin fibers. Please note that the data linking GAS2L2 to microtubule plus ends and interaction with EB1 are further supported by proteomics findings from PMID: 22885064.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24706950","rdfs:label":"GAS2L2 stabilizes microtubules and localizes to plus ends.","demonstrates":{"id":"cg:BiochemicalFunctionB"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/ad378f82-bd26-43d7-8b07-e901aafbcae9","type":"EvidenceLine","dc:description":"This experiment has not been scored, as the role of GAS2L2 in regulating cAMP production was not investigated in a ciliated cell type and surprisingly suggests a positive rather than a negative regulation of ciliary beat frequency.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6a2f452d-03fd-4fba-9da5-c1af9cf576eb","type":"Finding","dc:description":"This evidence is relevant to the potential role of GAS2L2 in ciliary dyskinesia since ciliary beating is known to be regulated by a balance between cAMP and Ca2+ ions (PMID: 32435198). Paradoxically, GAS2L2 appears to enhance cAMP production (presumably increasing ciliary beat frequency), while GAS2L2-deficient cells are typically hyperkinetic.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23994616","rdfs:label":"Exogenously expressed GAS2L2 regulates cAMP production.","demonstrates":{"id":"cg:BiochemicalFunctionB"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":0}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/91afae37-4cfc-4aeb-af0f-26a9596611f3_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8be6bede-9a36-4eab-8edf-bcee3473bd75","type":"EvidenceLine","dc:description":"This rescue validates the relevance of the model system to the human disease state by showing that human GAS2L2 mRNA can largely reverse the ciliary defect caused by targeting the orthologous Xenopus genes. The experiment was scored conservatively to reflect the fact that this single phenotype does not closely recapitulate the human disease state.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3787a44f-a3a6-410f-822f-ef6f2319ed9f","type":"Finding","dc:description":"RescueEvidence: Co-injection of human GAS2L2 mRNA substantially rescues the ciliary disorientation phenotype and increases the length of the ciliary beat direction vector to near-wild-type levels (Figure 6D).","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30665704","rdfs:label":"GAS2L2 rescue of ciliary disorientation in Xenopus embryos","demonstrates":{"id":"cg:PhenotypeRescue"}}],"specifiedBy":"GeneValidityNonHumanRescueCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/eaa5b4f7-37bf-4f2c-a4e3-299400aa6a9a","type":"EvidenceLine","dc:description":"Lower scoring has been recommended as the model is morpholino-based and recapitulates only the cellular level of the human defects.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/10257082-143d-42e4-8231-992dce732dae","type":"Finding","dc:description":"The embryos lacking Gas2l2 expression exhibit less effective ciliary motility (ciliary gliding defect) as well a abnormal ciliary morphology (shortening) relative to control embyros.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/36878953","rdfs:label":"Xenopus tropicalis embryo with Gas2l2 knockdown","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/8c227272-69b1-45a3-bb15-1c53bc42a41c","type":"EvidenceLine","dc:description":"The model does not harbor a known human variant but rather a morpholino-based disruption of expression from the two Gas2l2 loci. Down-scoring was performed due to the presence of cellular phenotypes only, the use of morpholinos, and the multiple Gas2l2 loci present.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3a5b5895-bdc5-4baa-ae20-ac19474151f9","type":"Finding","dc:description":"The Xenopus embryos subjected to Gas2l2 silencing exhibited ciliary dyskinesia in the form of ciliary disorientation (Figures 6B, 6C, 6B', 6C') and reduced length of the ciliary beat direction vector (Figure 6D). The disruption of anterior-to-posterior ciliary flow in these embryos recapitulated the defects of ciliated cells from the human patients. On the other hand, the presence of two Gas2l2 orthologs in this model organism (requiring two different morpholinos) reduces the degree of compatibility with the human disease state.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30665704","rdfs:label":"Gas2l2 silencing in Xenopus embryos","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/1ed79157-7abc-4228-b899-003d51825f00","type":"EvidenceLine","dc:description":"The model matches the human disease state at the cellular level, while its notable neonatal death and heterotaxy/dextrocardia phenotypes do not match the limited number of known human patients. The model matches the autosomal recessive mode of inheritance from the human patients, but harbors a complete disruption of the Gas2l2 locus rather than a known human variant.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/606e85d1-753b-44f6-a501-dd077db43779","type":"Finding","dc:description":"Heterozygous matings resulted in a high (29%) rate of neonatal death. Only 2 of the 265 surviving mice were homozygous knockouts of Gas2l2. This indicates that more than 95% of the expected homozygous offspring died as neonates. Mouse tracheal epithelial cell cultures showed hyperkinetic beat frequency (approximately 30% higher than wild-type, Figure 5B), misalignment of basal feet within each cell (Figure 5C) and reduced length of the vector representing ciliary beat direction (Figure 5D). Both of these matched observations of nasal cilia from the two human patients. Interestingly, neither dextrocardia nor other forms of heterotaxy have yet been observed among the limited number of human patients.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30665704","rdfs:label":"Gas2l2 knockout mouse","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/2a405122-7239-4446-a103-7b1c0b0b197d","type":"EvidenceLine","dc:description":"This conditional model complements the other knockout mouse model by bypassing its neonatal lethality and documenting upper respiratory issues reminiscent of the human sinusitis phenotype, while continuing to characterize ciliary motility defects.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/77ca2814-9258-48a1-aca9-5c8230b34e84","type":"Finding","dc:description":"The impaired nasal mucociliary clearance of the model was accompanied by disorientation of the ciliary beating pattern in each cell, which was reminiscent of the human patients. A small percentage of animals exhibited hydrocephalus (associated with PCD in mice). Abnormalities of the nasal cavity and mucus accumulation in the sinuses were also reminiscent of the human sinusitis phenotype (Figure S8).","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30665704","rdfs:label":"Gas2l2 conditional knockout mouse","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":3.5}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":5.5},{"id":"https://genegraph.clinicalgenome.org/r/91afae37-4cfc-4aeb-af0f-26a9596611f3_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/fbdcd2e2-42a5-4efa-ba18-433755f2bf9b_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/fbdcd2e2-42a5-4efa-ba18-433755f2bf9b","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/36104176","rdfs:label":"Feng_2022_Patient_1","ageType":"AgeAtReport","ageUnit":"Years","ageValue":24,"allele":{"id":"https://genegraph.clinicalgenome.org/r/7ca7e549-a628-4193-934f-25712a70d609","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_139285.4(GAS2L2):c.182C>T (p.Thr61Met)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA8506487"}},"detectionMethod":"Whole exome sequencing identified the variants in the GAS2L2 locus, which were subsequently confirmed by Sanger sequencing.","firstTestingMethod":"Exome sequencing","phenotypeFreeText":"The patient was 2 years old at time of symptomatic onset. The patient exhibited a productive wet cough, and TEM cross-section of bronchial tissue showed random orientation of respiratory cilia. Paranasal CT showed air-fluid level. One eardrum showed calcification and other showed absence of light reflex.","phenotypes":["obo:HP_0000246","obo:HP_0002110","obo:HP_0000370"],"previousTesting":true,"previousTestingDescription":"Previous testing consisted of whole-exome sequencing focused on PCD-related genes.","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/1e60ce9d-2677-4444-bea9-58cebab76be6_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/36104176","allele":{"id":"https://genegraph.clinicalgenome.org/r/7ca7e549-a628-4193-934f-25712a70d609"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Homozygous"}}},{"id":"https://genegraph.clinicalgenome.org/r/1e60ce9d-2677-4444-bea9-58cebab76be6","type":"EvidenceLine","dc:description":"NM_139285.4(GAS2L2):c.182C>T (p.Thr61Met) is a rare missense variant without evidence of functional impact on the gene product.","calculatedScore":0.2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1e60ce9d-2677-4444-bea9-58cebab76be6_variant_evidence_item"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.2}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.2},{"id":"https://genegraph.clinicalgenome.org/r/b8854b7c-9e23-4780-9f14-9f88beb94bf4_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b8854b7c-9e23-4780-9f14-9f88beb94bf4","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30665704","rdfs:label":"Bustamante-Marin_2019_Proband_DCP-1040","ageType":"AgeAtReport","ageUnit":"Years","ageValue":11,"allele":[{"id":"https://genegraph.clinicalgenome.org/r/abf42628-b584-43f0-b8fd-6375892f037a","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_139285.4(GAS2L2):c.887_890del (p.Val296fs)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/633450"}},{"id":"https://genegraph.clinicalgenome.org/r/ac7a2e3a-7179-4a61-bc71-862375b76dbc","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000017.11:g.35743303_35747235del (GRCh38)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2573050552"}}],"detectionMethod":"Next-generation sequencing, including copy-number analysis based on read-depth, was used to define the variants in the GAS2L2 locus (in one case extending into the adjacent RASL10B locus).","firstTestingMethod":"Other","phenotypeFreeText":"Nasal nitric oxide was 47 nL/min. Ciliated cells from the patient exhibited  a normal waveform but a hyperkinetic beat frequency. Basal body orientation was also disrupted, causing an abnormality in the direction of ciliary beating.","phenotypes":["obo:HP_0000246","obo:HP_0033036","obo:HP_0000388","obo:HP_0012265","obo:HP_0002110"],"previousTesting":true,"previousTestingDescription":"Previous testing was triggered by clinical phenotyping for PCD and consisted of either Sanger sequencing or whole-exome sequencing (not specified) to identify variants in the GAS2L2 locus.","secondTestingMethod":"Other","sex":"Female","variant":[{"id":"https://genegraph.clinicalgenome.org/r/7b858731-464b-499b-b6cc-552bdd804a95_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30665704","allele":{"id":"https://genegraph.clinicalgenome.org/r/ac7a2e3a-7179-4a61-bc71-862375b76dbc"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}},{"id":"https://genegraph.clinicalgenome.org/r/bc53fdfe-0445-4323-9a50-fd5095fb6df3_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30665704","allele":{"id":"https://genegraph.clinicalgenome.org/r/abf42628-b584-43f0-b8fd-6375892f037a"},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}]},{"id":"https://genegraph.clinicalgenome.org/r/bc53fdfe-0445-4323-9a50-fd5095fb6df3","type":"EvidenceLine","dc:description":"NM_139285.4(GAS2L2):c.887890del (p.Val296fs) is a four-bp deletion variant predicted to trigger a frameshift. This variant occurs in exon 5 (of 6 total exons), more than 50bp upstream of the last exon junction in the transcript. It is therefore predicted to trigger NMD, and at least disrupts the C-terminal ~66% of the protein product. The variant has been down-scored since it has been previously scored in another patient from the same paper. This variant was not dramatically down-scored despite the complicating factor that the large deletion variant in trans disrupts more than the GAS2L2 locus, since the adjacent RASL10B gene is not known to be involved in PCD.","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/bc53fdfe-0445-4323-9a50-fd5095fb6df3_variant_evidence_item"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/7b858731-464b-499b-b6cc-552bdd804a95","type":"EvidenceLine","dc:description":"NC_000017.11:g.35743303_35747235del is a large deletion variant predicted to trigger a frameshift. This variant occurs in exon 5 (of 6 total exons), more than 50bp upstream of the last exon junction in the transcript. It is therefore predicted to trigger NMD, and at least disrupts the C-terminal ~67% of the protein product. Scoring has been downgraded because the deletion also disrupts the adjacent locus, disrupting part of the 3'UTR of the RASL10B transcript. Some scoring was preserved since the adjacent RASL10B gene is not known to be involved in PCD.","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7b858731-464b-499b-b6cc-552bdd804a95_variant_evidence_item"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/f62d827f-13b6-431f-b1f9-20f7df44d5d9_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f62d827f-13b6-431f-b1f9-20f7df44d5d9","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30665704","rdfs:label":"Bustamante-Marin_2019_Proband_PCD-1367","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":56,"allele":{"id":"https://genegraph.clinicalgenome.org/r/abf42628-b584-43f0-b8fd-6375892f037a"},"detectionMethod":"Whole exome sequencing identified the variants in the GAS2L2 locus, which were subsequently confirmed by Sanger sequencing.","firstTestingMethod":"Exome sequencing","phenotypeFreeText":"Nasal nitric oxide was 342.6 nL/min. Ciliated cells from the patient exhibited  a normal waveform but a hyperkinetic beat frequency. Basal body orientation of basal bodies was also disrupted, causing an abnormality in the direction of ciliary beating.","phenotypes":["obo:HP_0012265","obo:HP_0002110","obo:HP_0003251","obo:HP_0000388","obo:HP_0000246"],"previousTesting":false,"previousTestingDescription":"Previous testing consisted only of clinical phenotyping for PCD.","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/f19a70a5-7c82-4bb0-b457-deb45e439d53_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30665704","allele":{"id":"https://genegraph.clinicalgenome.org/r/abf42628-b584-43f0-b8fd-6375892f037a"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}},{"id":"https://genegraph.clinicalgenome.org/r/f19a70a5-7c82-4bb0-b457-deb45e439d53","type":"EvidenceLine","dc:description":"NM_139285.4(GAS2L2):c.887_890del (p.Val296fs) is four-bp deletion variant predicted to trigger a frameshift. This variant occurs in exon 5 (of 6 total exons), more than 50bp upstream of the last exon junction in the transcript. It is therefore predicted to trigger NMD, and at least disrupts the C-terminal ~66% of the protein product. The variant has been down-scored due to its presence in a homozygous state.","calculatedScore":3.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f19a70a5-7c82-4bb0-b457-deb45e439d53_variant_evidence_item"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":3.7}],"evidenceStrength":"Moderate","sequence":7355,"specifiedBy":"GeneValidityCriteria9","strengthScore":9.2,"subject":{"id":"https://genegraph.clinicalgenome.org/r/vBjO2o4Ux_g","type":"GeneValidityProposition","disease":"obo:MONDO_0032757","gene":"hgnc:24846","modeOfInheritance":"obo:HP_0000007"},"version":"3.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_91afae37-4cfc-4aeb-af0f-26a9596611f3-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}